Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

A survey of the clinical usage of intra-articular therapeutics in dogs by veterinary practitioners with a focus on non-steroidal therapies

Sepulveda CP., Corriveau KM., Boone LH., Hofmeister EH., Kane MR., Lascola KM.

Prospective Study with a reported sample of 164 on Osteoarthritis, published in Front Vet Sci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Front Vet Sci (2026)
Reported sample size
164
Source database
Europe PMC
PMID
41756585
PMCID
PMC12932153
DOI
10.3389/fvets.2026.1761681

Abstract (original English)

Osteoarthritis (OA) is a degenerative condition of the joint, whose progressive characteristics can lead to significant functional impairment and pain in the canine patient. Interest has increased regarding the use of intra-articular (IA) therapeutics as part of the multimodal management of canine OA. This study aimed to present the clinical experience of surgery and rehabilitation practitioners using these therapeutics to better understand their clinical usage, perceived outcomes, and clinical reasoning for product usage. A survey inquiring about IA injections with a focus on non-steroidal intra-articular therapeutics (NSIATs), including platelet-rich plasma (PRP), autologous conditioned serum (ACS), autologous protein solution (APS), cellular therapy, viscosupplements, and radionuclide, was distributed to canine practitioners. A total of 174 surveys were included in the results. Intra-articular injections were performed by 164 participants. Among these, 144 practitioners used NSIATs. The most common joint injected with steroidal and/or NSIATs was the elbow. The top reason for participants' decision as to which NSIATs they preferentially used was scientific data and articles published regarding the product's safety and efficacy. The most used NSIATs were PRP and viscosupplements, followed by cellular therapy, radionuclides, ACS, and APS. Practitioners reported that the most co

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research